Pure Lithium Expands Strategic Vanadium Cathode Technology Portfolio with Asset Acquisition from Private US Based Dimien Inc.
Pure Lithium Corporation, a disruptive Boston-based vertically integrated lithium metal battery technology company, is pleased to announce the acquisition of all the assets of Dimien Inc., a private U.S. vanadium cathode materials company. Pure Lithium acquired Dimien’s intellectual property, know-how, manufacturing equipment and took on its experienced team, accelerating the development of Pure Lithium’s lithium metal vanadium (LVO) battery.
Dimien developed a class of vanadium-based cathode material known as zeta vanadium oxide (ZVO). This low-cost cathode material has high energy density and does not cause fires like today’s NMC and NCA cathodes. Dimien’s vanadium cathode is made from materials that are produced in North America and does not use minerals such as nickel, cobalt and graphite, which are sourced from less favorable jurisdictions, and are at risk of short supply in the future.
Dr. Brian Schultz, Founder and CEO of Dimien, will join Pure Lithium in the role of Vice President of Business Development and Technology. Additional Dimien team members will also join the company.
Pure Lithium Founder and CEO Emilie Bodoin commented:
“This asset purchase will expedite the commercialization of our LVO battery. Dr. Schultz and his team have worked diligently for years to develop a vanadium cathode. They have taken ZVO from a university science project to commercially relevant prototypes, which cycle beautifully against our lithium metal. I have known Dr. Schultz for several years, and he is a fantastic, meticulous scientist and I am thrilled to have him join the Pure Lithium team.”
“We have a lithium metal electrode production technology that dramatically reduces costs, and together with our LVO battery technology, we will bring to market a next-generation battery that is superior to lithium-ion in performance and safety. Eliminating graphite, nickel and cobalt is disruptive for the industry, and will ensure U.S. supply chain security ending dependence on China.”
“It is well known by battery manufacturing incumbents that vanadium is not technically viable for use in lithium-ion batteries, which utilize a graphite anode and a lithiated transition metal oxide cathode. Ironically however, the same reasons that vanadium is not viable for lithium-ion technology make it the perfect pairing for Pure Lithium’s next-generation lithium metal batteries, presenting a unprecedented commercial opportunity for Pure Lithium.”
Dimien Founder and CEO, Brian Schultz, comments:
“We are thrilled to announce the sale of all the assets of our company to Pure Lithium and our new journey with the Pure Lithium team. This sale marks a significant milestone in Dimien’s journey, reflecting our team’s dedication to growth, innovation and the pursuit of clean energy technologies. I want to thank everyone who has supported our vision as this exit would not have been possible without the dedication of many great people.”
“I’ve known Emilie for several years and have watched her build a truly talented team and develop disruptive technology poised to commercially break through. The combination of Pure Lithium’s lithium metal anode with Dimien’s vanadium cathode is an ideal pairing that will accelerate the commercialization of advanced battery technology. Joining forces with Pure Lithium is an exciting next step, and we can’t wait to get started!”
To learn more about how Pure Lithium is revolutionizing battery production, go to: https://www.purelithium.io/
View source version on businesswire.com: https://www.businesswire.com/news/home/20240930266814/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 14:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom